Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential | Pfizer
ELEVATE UC 52 met the co-primary endpoints of clinical remission at both weeks 12 and 52 and all key secondary endpoints - Etrasimod demonstrated a safety profile consistent with previous studies Pfizer Inc. (NYSE: PFE) today announced positive top-line results from a second Phase 3 study of...
www.pfizer.com